TAS-102 plus bevacizumab is cost-effective in China but not in the US or UK due to high incremental cost-effectiveness ratios (ICERs). The study uses a decision model to compare TAS-102 monotherapy ...
Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Incremental cost is the total cost incurred ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results